Quantitative Analysis of Inclisiran‐Oligonucleotide Therapy of Atherosclerotic Cardiovascular Disease Through Internal Standard‐Mediated Liquid Chromatography‐High‐Resolution Mass Spectrometry
SEPARATION SCIENCE PLUS · 2026-10 · 9 (10)
DOI: 10.1002/sscp.70329 ↗Kurz gefasst
Fachartikel in der Zeitschrift SEPARATION SCIENCE PLUS, online erschienen am 11.10.2026. Verfasst von Yogesh M. Tekale und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India.
Abstract (Originalsprache)
Oligonucleotides have increased their applicability in various fields, including Pharmaceuticals, in the past decade. The quantification of oligonucleotides through separation techniques has been a constant need. Quantifying these oligonucleotides by liquid chromatography‐ultraviolet (LC‐UV) is challenging because structurally similar impurities/degradation products have the same UV profile and co‐elute with the drug. This limits the attainment of regulatory requirements. The current study focused on developing a quantitative assessment analytical method for quality control of Inclisiran (INC), a small interfering RNA (siRNA) duplex oligonucleotide. We achieved a reasonable separation using ion‐pair reversed‐phase LC. The accurate quantification of the analyte was performed using high‐resolution mass spectrometry (HRMS) with an extracted ion chromatogram (EIC) processing approach. In order to accommodate variations in the mass spectrometer's signal intensity between runs, Tofersen was used as an internal standard (IS). The stressed degradation samples were run to confirm the hypothesis. The developed method was also validated to ensure compliance with the USP and ICH Q2(R2) regulatory frameworks. The quality control assay method was found to be rapid yet selective and specific to INC. A linear response was observed over 50%–150% of the target concentration range. The recovery of the analyte in the formulation matrix was determined by injecting triplicate measurements at three distinct concentration levels to ensure accuracy. The recovery was found within the 95%–105% range. The method demonstrated robustness against changes in LC and MS parameters, such as injection volume, flow rate, gas flow, and drying/desolvation temperature. This approach will provide a unique combination of IS and EIC‐based exact mass analyses for duplex siRNA oligonucleotides for improved accuracy.
Förderung
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
Zitieren
APA
Tekale, Y. M., Bhalekar, V. S., & Shah, R. P. (2026). Quantitative Analysis of Inclisiran‐Oligonucleotide Therapy of Atherosclerotic Cardiovascular Disease Through Internal Standard‐Mediated Liquid Chromatography‐High‐Resolution Mass Spectrometry. SEPARATION SCIENCE PLUS, 9(10). https://doi.org/10.1002/sscp.70329
Vancouver
Tekale YM, Bhalekar VS, Shah RP. Quantitative Analysis of Inclisiran‐Oligonucleotide Therapy of Atherosclerotic Cardiovascular Disease Through Internal Standard‐Mediated Liquid Chromatography‐High‐Resolution Mass Spectrometry. SEPARATION SCIENCE PLUS. 2026;9(10). doi:10.1002/sscp.70329
BibTeX
@article{Tekale2026,
author = {Tekale, Yogesh M. and Bhalekar, Vijay S. and Shah, Ravi P.},
title = {Quantitative Analysis of Inclisiran‐Oligonucleotide Therapy of Atherosclerotic Cardiovascular Disease Through Internal Standard‐Mediated Liquid Chromatography‐High‐Resolution Mass Spectrometry},
journal = {SEPARATION SCIENCE PLUS},
year = {2026},
volume = {9},
number = {10},
doi = {10.1002/sscp.70329}
}
EUVIMED